Same-day 2-L PEG-citrate-simethicone plus bisacodyl vs split 4-L PEG: Bowel cleansing for late-morning colonoscopy

Table 1 Patients characteristics

Variable	PEG-CS + Bis (n = 78)	PEG (n = 79)
Male	30 (38.5)	27 (34.2)
Age (yr)	61.8 ± 10.8	60.9 ± 12.0
Height (cm)	166.2 ± 9.1	165.0 ± 8.1
Weight (kg)	68.4 ± 14.5	68.6 ± 13.4
BMI (kg/m2)	24.6 ± 3.8	25.1 ± 4.1

Data are expressed as absolute numbers (percentage) or mean ± SD. PEG-CS + Bis: Polyethyleneglycol-citrate-simeticone+ bisacodyl; PEG: Polyethyleneglycol; BMI: Body mass index.

Table 2 Efficacy results

	PEG-CS + Bis (n = 78)	PEG (n = 76)1
Overall OBPS score	3.09 ± 2.40	2.39 ± 2.55
Caecal intubation rate	76 (97.4)	75 (98.7)
Time (min) to reach the caecum	10.90 ± 6.1	9.80 ± 3.6
Adenoma detection	34 (43.6)	34 (44.7)

Data are expressed as absolute numbers (percentage) or mean ± SD.

¹Three patients did not complete the study (see Figure 1). PEG-CS + Bis: Polyethyleneglycol-citrate-simeticone+ bisacodyl; PEG: Polyethyleneglycol.

Table 3 Tolerability and acceptability n (%)

	PEG-CS + Bis (n = 78)	PEG (n = 79)
GI tolerability
Nausea (no or mild)	73 (93.6)	72 (91.1)
Bloating (no or mild)	77 (98.7)	78 (98.7)
Abdominal pain/cramps (no or mild)	73 (93.6)	77 (97.5)
Anal irritation (no or mild)	75 (96.1)	77 (97.5)
Adverse events
Vomiting	6 (7.7)	2 (2.5)
Sweating	2 (2.6)	0 (0.0)
Headache	3 (3.8)	3 (3.8)
Shivering	2 (2.6)	1 (1.3)
Pre-syncope	2 (2.6)	0 (0.0)
Acceptability
Easy of intake (no distress)	51 (65.4)	48 (60.8)
Willingness to repeat the same regimen	67 (85.9)	71 (89.9)
Preference to current regimen1	23 (82.1)	26 (68.4)
Urgency during the journey (no or mild)	78 (100.0)	79 (100.0)
Interference with sleeping (no or mild)	71 (91.0)	76 (96.2)

¹Excluding patients with first colonoscopy, missing data or unable to remember the first preparation. PEG-CS + Bis: Polyethyleneglycol-citrate-simeticone+ bisacodyl; PEG: Polyethyleneglycol; GI: Gastrointestinal.